BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 12563361)

  • 1. [The role of adjuvant clodronate therapy for prevention of bone metastasis in breast cancer].
    Horváth Z
    Magy Onkol; 2002; 46(4):361-4. PubMed ID: 12563361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduction in new metastases in breast cancer with adjuvant clodronate treatment.
    Diel IJ; Solomayer EF; Costa SD; Gollan C; Goerner R; Wallwiener D; Kaufmann M; Bastert G
    N Engl J Med; 1998 Aug; 339(6):357-63. PubMed ID: 9691101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of bisphosphonates in prevention and treatment of bone metastases from breast cancer.
    Paterson AH; Kanis JA; Powles TJ; McCloskey E; Hanson J; Ashley S
    Can J Oncol; 1995 Dec; 5 Suppl 1():54-7. PubMed ID: 8853526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral bisphosphonates as adjuvant therapy for operable breast cancer.
    Powles T; McCroskey E; Paterson A
    Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6301s-6304s. PubMed ID: 17062718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical trials in metastatic breast cancer to bone: past--present--future.
    Body JJ
    Can J Oncol; 1995 Dec; 5 Suppl 1():16-27. PubMed ID: 8853520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases].
    Tubiana-Hulin M; Beuzeboc P; Mauriac L; Barbet N; Frenay M; Monnier A; Pion JM; Switsers O; Misset JL; Assadourian S; Bessa E
    Bull Cancer; 2001 Jul; 88(7):701-7. PubMed ID: 11495824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
    Clemons MJ; Dranitsaris G; Ooi WS; Yogendran G; Sukovic T; Wong BY; Verma S; Pritchard KI; Trudeau M; Cole DE
    J Clin Oncol; 2006 Oct; 24(30):4895-900. PubMed ID: 17001071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant bisphosphonates in breast cancer: are we witnessing the emergence of a new therapeutic strategy?
    Coleman RE
    Eur J Cancer; 2009 Jul; 45(11):1909-15. PubMed ID: 19447606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Should oral bisphosphonates be standard of care in women with early breast cancer?
    Clemons M; Verma S
    Breast Cancer Res Treat; 2005 Apr; 90(3):315-8. PubMed ID: 15830146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aredia: the once-monthly infusion for the treatment of bone metastases.
    Lipton A
    Curr Opin Oncol; 1998 Aug; 10 Suppl 1():S1-5. PubMed ID: 9801852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral pamidronate in the prevention and treatment of skeletal metastases in patients with breast cancer.
    van Holten-Verzantvoort AT; Papapoulos SE
    Medicina (B Aires); 1997; 57 Suppl 1():109-13. PubMed ID: 9567363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026].
    Powles T; Paterson A; McCloskey E; Schein P; Scheffler B; Tidy A; Ashley S; Smith I; Ottestad L; Kanis J
    Breast Cancer Res; 2006; 8(2):R13. PubMed ID: 16542503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bisphosphonates: clinical experience.
    Coleman RE
    Oncologist; 2004; 9 Suppl 4():14-27. PubMed ID: 15459426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant bisphosphonate therapy for breast cancer patients: Standard of care or future direction?
    Freedman OC; Amir E; Clemons MJ
    Crit Rev Oncol Hematol; 2009 Oct; 72(1):56-64. PubMed ID: 19307138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Three-year oral clodronate treatment does not impair mineralization of newly formed bone--a histomorphometric study.
    Saarto T; Taube T; Blomqvist C; Vehmanen L; Elomaa I
    Calcif Tissue Int; 2005 Aug; 77(2):84-90. PubMed ID: 16075363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacotherapy of bone metastases in breast cancer patients.
    Petrut B; Simmons C; Broom R; Trinkaus M; Clemons M
    Expert Opin Pharmacother; 2008 Apr; 9(6):937-45. PubMed ID: 18377337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bisphosphonates for the prevention of bone metastases.
    Coleman RE
    Semin Oncol; 2002 Dec; 29(6 Suppl 21):43-9. PubMed ID: 12584694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toward new horizons: the future of bisphosphonate therapy.
    Lipton A
    Oncologist; 2004; 9 Suppl 4():38-47. PubMed ID: 15459428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of bisphosphonates in early breast cancer.
    Paterson AH
    Oncologist; 2006; 11 Suppl 1():13-9. PubMed ID: 16971735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Approaches to managing bone metastases from breast cancer: the role of bisphosphonates.
    Mystakidou K; Katsouda E; Stathopoulou E; Vlahos L
    Cancer Treat Rev; 2005 Jun; 31(4):303-11. PubMed ID: 16039956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.